Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Mar 30, 2018 • 9:00 AM EDT
Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
Mar 6, 2018 • 4:01 PM EST
Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
Mar 5, 2018 • 4:01 PM EST
Ligand to Participate in Two Upcoming Investor Conferences
Mar 13, 2018 • 8:30am EDT
See all events
Mar 12, 2018 • 4:30pm EDT
Dana Point, California
Feb 21, 2018 • 4:30pm EDT
$SYRS announces new preclinical data on Captisol-enabled SY-1365 showing potent anti-tumor activity in multiple mod… https://t.co/kTytckvWJc
$APVO OmniAb-derived bispecific antibody APVO436 shows robust T-Cell activation with minimal cytokine release in pr… https://t.co/EklRBCJgLg
$SAGE to present Brexanolone postpartum depression data at upcoming spring medical meetings https://t.co/dtUw9ERNCQ